Brief: Allovir Says Pursuant To Letter From Nasdaq, Allovir Is Not In Compliance With Nasdaq Listing Rule 5450(A)(1)

Kalaris Therapeutics

12/02/2024 22:45

Feb 12 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR - ON FEB 9, GOT LETTER FROM NASDAQ THAT CLOSING
BID
PRICE OF CO’S COMMON STOCK WAS BELOW $1.00 PER SHARE FOR 30
CONSECUTIVE BUSINESS DAYS
    * ALLOVIR INC - PURSUANT TO LETTER FROM NASDAQ, ALLOVIR IS
NOT IN
COMPLIANCE WITH NASDAQ LISTING RULE 5450(A)(1)

Source text for Eikon:  ID:n0001193125-24-032160 
Further company coverage:  ALVR.O 

 ((reuters.briefs@thomsonreuters.com;))